

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM780017

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Evening Post Group, LLC		01/11/2023	Limited Liability Company: SOUTH CAROLINA
RECEIVING PARTY DATA			
Name:	EPI Health, LLC		
Street Address:	134 Columbus Street		
City:	Charleston		
State/Country:	SOUTH CAROLINA		
Postal Code:	29403		
Entity Type:	Limited Liability Company: SOUTH CAROLINA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	5232934	RHOFAD E	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9198211220		
Email:	trademarks@smithlaw.com		
Correspondent Name:	Eva Gullick Frongello		
Address Line 1:	P.O. Box 2611		
Address Line 4:	Raleigh, NORTH CAROLINA 27602		
ATTORNEY DOCKET NUMBER:	12219.1		
NAME OF SUBMITTER:	Eva Gullick Frongello		
SIGNATURE:	/Eva Gullick Frongello/		
DATE SIGNED:	01/11/2023		
Total Attachments: 16			
source=EPI Health Termination and Release of Security Interests#page1.tif			
source=EPI Health Termination and Release of Security Interests#page2.tif			
source=EPI Health Termination and Release of Security Interests#page3.tif			
source=EPI Health Termination and Release of Security Interests#page4.tif			

CH \$40.00 5232934

source=EPI Health Termination and Release of Security Interests#page5.tif
source=EPI Health Termination and Release of Security Interests#page6.tif
source=EPI Health Termination and Release of Security Interests#page7.tif
source=EPI Health Termination and Release of Security Interests#page8.tif
source=EPI Health Termination and Release of Security Interests#page9.tif
source=EPI Health Termination and Release of Security Interests#page10.tif
source=EPI Health Termination and Release of Security Interests#page11.tif
source=EPI Health Termination and Release of Security Interests#page12.tif
source=EPI Health Termination and Release of Security Interests#page13.tif
source=EPI Health Termination and Release of Security Interests#page14.tif
source=EPI Health Termination and Release of Security Interests#page15.tif
source=EPI Health Termination and Release of Security Interests#page16.tif

TERMINATION AND RELEASE OF SECURITY AGREEMENT

This TERMINATION AND RELEASE OF SECURITY AGREEMENT ("Termination and Release") dated and effective as of January 11, 2023, is made by EVENING POST GROUP, LLC, a South Carolina limited liability company and its successors or assigns ("Grantee"), in favor of EPI HEALTH, LLC, a South Carolina limited liability company ("Grantor").

WITNESSETH:

WHEREAS, in consideration of that certain extension of credit by Grantee to NOVAN, Inc., a Delaware corporation (the "Borrower"), pursuant to that certain Secured Promissory Note and Security Agreement dated as of March 11, 2022 (as amended, modified, restated or replaced from time to time, the "Note Agreement") among the Borrower and Grantee, Grantor entered into that certain Guaranty Agreement dated as of March 11, 2022 (as the same may be amended, amended and restated, modified or otherwise supplemented from time to time, the "Guaranty"; capitalized terms not otherwise defined herein shall have meanings assigned to such terms in the Guaranty and in the Note Agreement).

WHEREAS, as a condition precedent to the effectiveness of the Note Agreement, Grantor executed that certain Security Agreement dated as of March 11, 2022 between Grantor and Grantee and in favor of Grantee, and granted to the Grantee a lien on and security interest in certain collateral as defined in the Security Agreement (the "Security Agreement").

WHEREAS, the Security Agreement was recorded with the United States Patent and Trademark Office ("USPTO") at Reel 059364 Frame 0511 on March 14, 2022, pursuant to which Grantor granted a security interest to Grantee in Grantor's intellectual property, including certain patents, patent applications, trademarks and/or trademarks applications (the "Intellectual Property") listed on Schedule A attached hereto and made a part hereof.

WHEREAS, on July 13, 2022, Borrower, Grantor, and Grantee entered into that certain Prepayment and Termination Letter Agreement, pursuant to which Grantee agreed to terminate and release its security interest in the Intellectual Property listed on Schedule A attached hereto.

NOW, THEREFORE, for good and valuable consideration, receipt, and sufficiency of which are hereby acknowledged:

1. Grantee hereby confirms and agrees that its security interest in all of Grantor's right, title, and interest in and to the Intellectual Property set forth on Schedule A has been terminated and released, and Grantee reassigns, without representation, warranty or recourse by Grantee, all interest of Grantee in the Intellectual Property.

2. Grantee agrees to take all further actions and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or instruments, as the Grantor and its successors, assigns, and legal representatives may reasonably request in order to confirm, effectuate or record this Termination and Release.

IN WITNESS WHEREOF, Grantee has caused this Termination and Release to be duly executed and delivered as of the date first written above.

EVENING POST GROUP, LLC

By: Joe Waring

Name: Joe Waring

Title: CFO / EVP

SCHEDULE A

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
United States of America	12/707,369	8,211,466	Jul 3, 2012	Epi Health, LLC	MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES
United States of America	13/565,653	8,747,896	Jun 10, 2014	Epi Health, LLC	MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES
United States of America	13/943,504	8,791,127	Jul 29, 2014	Epi Health, LLC	MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES
Canada	2,647,123	2,647,123	Aug 6, 2013	Epi Health, LLC	MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES
United States of America	12/634,225	8,592,434	Nov 26, 2013	Epi Health, LLC	MUCOSAL BIOADHESIVE TABLETS FOR THE TREATMENT OF OROFACIAL HERPES
Canada	2,782,779	2,782,779	Jul 14, 2015	Epi Health, LLC	MUCOADHESIVE BUCCAL TABLETS FOR THE TREATMENT OF OROFACIAL HERPES
United States of America	10/307,938	6,916,485	Jul 12, 2005	Vectans Pharma	Prolonged release bioadhesive therapeutic systems
Canada	2,455,633	2,455,633	May 1, 2012	Vectans Pharma	SUSTAINED-RELEASE THERAPEUTIC BIOADHESIVE SYSTEMS
European Patent Office	07006150.2	1792610	Oct 15, 2008	Vectans Pharma	SUSTAINED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
European Patent Office	02774826.8	1408911	Sep 19, 2007	Vectans Pharma	SUSTAINED-RELEASE THERAPEUTIC BIOADHESIVE SYSTEMS
France	0109811	2827517	Oct 24, 2003	Vectans Pharma	Prolonged release mucosal bioadhesive tablets for treating Candida infections, comprising fungicide
European Patent Office	07734862.1	1998750	Oct 28, 2009	Vectans Pharma	MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES
European Patent Office	10792884.8	2509586	May 2, 2018	Vectans Pharma	MUCCOADHESIVE BUCCAL TABLETS FOR THE TREATMENT OF OROFACIAL HERPES

Rhofade Patents Owned by EPI Health

United States of America	12/272,253	8,114,898	Feb 14, 2012	Epi Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
European Patent Office	08850846.0	2207424	Jun 4, 2014	ALLERGAN, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Japan	2010-534258	5670196	Dec 26, 2014	Allergan Sales, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Canada	2,703,109	2,703,100	Jul 18, 2017	Epi Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Mexico	MX/a/2010/00533.1	334896	Nov 18, 2015	Epi Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Australia	2008322411	2008322411	Jul 17, 2014	Epi Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
China	200880116406.9	101896204	May 20, 2015	Epi Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
United States of America	13/345,472	8,673,953	Mar 18, 2014	Epi Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
European Patent Office	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Japan	2014-214612	5938082	May 20, 2016	Allergan Sales, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Israel	205704	205704	Oct 1, 2015	Epi Health, LLC	USE OF ALPHA ADRENERGIC RECEPTOR AGONISTS IN THE PREPARATION OF A MEDICAMENT FOR TREATING PURPURA
United States of America	14/181.706	9,265,761	Feb 23, 2016	EPI Health, LLC	COMPOSITIONS AND METHODS FOR TREATING PURPURA
European Patent Office	18202816.7			ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Republic of Korea	10-2010-7013170	10-1577471	Dec 14, 2015	ALLERGAN, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
France	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Germany	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Italy	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Spain	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
Switzerland	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
United Kingdom	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Germany	8850846.0	2207424	Jun 4, 2014	Aclaris Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
France	08850846.0	2207424	Jun 4, 2014	ALLERGAN, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
United Kingdom	08850846.0	2207424	Jun 4, 2014	Aclaris Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Luxembourg	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Monaco	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Norway	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Portugal	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Sweden	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Turkey	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Austria	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Croatia	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
Czechia	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Finland	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Greece	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Hungary	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Iceland	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Poland	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Romania	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Slovakia	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Slovenia	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Belgium	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Denmark	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Ireland	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA
Netherlands	14170999.8	2818184	Oct 31, 2018	ACLARIS THERAPEUTICS, INC.	COMPOSITIONS AND METHODS FOR TREATING PURPURA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
United States of America	13/309,403	8,883,838	Nov 11, 2014	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE
European Patent Office	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Japan	2013-542183	6030067	Oct 28, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Canada	2819633	2819633	Apr 23, 2019	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Australia	2011336449	2011336449	Oct 20, 2016	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Taiwan (Province of China)	100144568	I533893	May 21, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
United States of America	14/521,094			EPI Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE
European Patent Office	16196317.8	3181121	Oct 28, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA
Germany	1619617.8	3181121	Oct 28, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA
Spain	300384503	3181121	Oct 28, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA
France	1619617.8	3181121	Oct 28, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
United Kingdom	1619617.8	3181121	Oct 28, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA
Italy	502021000001691	3181121	Oct 28, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE TO TREAT ROSACEA
Hong Kong	14103376.2	HK1190307	Jan 5, 2018	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Australia	2018229508	2018229508	Oct 8, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Austria	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Belgium	1.1794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Switzerland	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Czechia	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Germany	11794911.5	60 2011 031 996.5	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Denmark	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Spain	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
France	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
United Kingdom	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Greece	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Ireland	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Italy	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Netherlands	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Norway	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Poland	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Portugal	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Romania	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Sweden	11794911.5	2645993	Nov 2, 2016	Aclaris Therapeutics, Inc.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
Turkey	11794911.5	2645993	Nov 2, 2016	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE
United States of America	16/798,176			EPI Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
European Patent Office	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Japan	2013-554551	6225030	Oct 13, 2017	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Canada	2,827,373	2,827,373	May 14, 2019	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Brazil	BR11 2013020770 -1			ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
European Patent Office	19170085.5			Epi Health, LLC	PHARMACEUTICAL COMPOSITION COMPRISING OXYMETAZOLINE
Japan	2017-002106	6389534	Aug 24, 2018	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR SYMPTOMS OF ROSACEA
Australia	2017202726	2017202726	Jun 20, 2019	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR SYMPTOMS OF ROSACEA
China	2017 0)280045.2			Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR SYMPTOMS OF ROSACEA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
Hong Kong	14105951.0	11192724	Jul 10, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR SYMPTOMS OF ROSACEA
Australia	2019203993	2019203993	Sep 10, 2020	Epi Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR SYMPTOMS OF ROSACEA
Republic of Korea	10-2013-7024232	10-2058756	Dec 17, 2019	ACLARIS THERAPEUTICS INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR SYMPTOMS OF ROSACEA
Russian Federation	2013141845	2648439	Mar 26, 2018	ALLERGAN, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
France	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Germany	12705755.2	60 2012 059 308.3	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Italy	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Netherlands	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
Spain	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
Switzerland	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
United Kingdom	12705755.2	2675449	Apr 24, 2019	ACLARIS THERAPEUTICS, INC.	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA
United States of America	16/673,549			EPI Health, LLC	PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE
United States of America	14/737,360	9,801,857	Oct 31, 2017	Epi Health, LLC	STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
European Patent Office	15738161.7	3154517	Apr 22, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Germany	602015051147.6	3154517	Apr 22, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Spain	15738161.7	2796871	Apr 22, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
France	15738161.7	3154517	Apr 22, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
United Kingdom	15738161.7	3154517	Apr 22, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Italy	502020000049354	3154517	Apr 22, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Canada	2,951,725			Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Mexico	MX/a/2016/016400	379253	Jan 22, 2021	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
Australia	2015274532	2015274532	Oct 15, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
New Zealand	727233			Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
United States of America	15/429,873	9,974,773	May 22, 2018	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
United States of America	15/984,918	10,335,391	Jul 2, 2019	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Hong Kong	17110194.4	123639.1	Jan 22, 2021	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
United States of America	16/380,538	10,751,325	Aug 25, 2020	Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
United States of America	16/924,782			Epi Health, LLC	STABILIZED FORMULATIONS AND THEIR USES
Rhofade Patents Licensed by Allergan to EPI Health					
United States of America	10/763,807	7,812,049	Oct 12, 2010	Allergan, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a 1-adrenoceptor agonists
United States of America	12/788,746	8,420,688	Apr 16, 2013	Allergan, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using al-adrenoceptor agonists
United States of America	12;901,755	8,815,929	Aug 26, 2014	Allergan, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using al-adrenoceptor agonists
United States of America	12/901,911	8,877,793	Nov 4, 2014	Allergan, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using al-adrenoceptor agonists

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
United States of America	16/857,968			Allergan, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using al-adrenoceptor agonists
Minlora Patents and Applications Licensed from Dr. Reddy's Laboratories Ltd.					
United States of America	15/093,673	11,103,517	Aug 31, 2021	Dr. Reddy's Laboratories Ltd.	PHARMACEUTICAL COMPOSITIONS FOR MINOCYCLINE
United States of America	17/388,133			Dr. Reddy's Laboratories Ltd.	PHARMACEUTICAL COMPOSITIONS FOR MINOCYCLINE
United States of America	11/695,528	7,541,347	Jun 2, 2009	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
United States of America	12/875,876	8,268,804	Sep 18, 2012	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
United States of America	12/253,845	7,790,705	Sep 7, 2010	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
United States of America	12/861,424	8,722,650	May 13, 2014	Medicis Pharmaceutical Corporation	Extended-release minocycline dosage forms
United States of America	11/695,539	7,544,373	Jun 9, 2009	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
United States of America	11/166,817	7,919,483	Apr 5, 2011	Medicis Pharmaceutical Corporation	Method for the treatment of acne
United States of America	11/695,513	8,252,776	Aug 28, 2012	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
United States of America	12/536,359	9,192,615	Nov 24, 2015	Medicis Pharmaceutical Corporation	Minocycline for the treatment of acne and certain dosage forms thereof
Nuvail					

Country	Application Number	Patent Number	Grant Date	Owner of Record	Title
United States of America	10/757,294	7,008,997	Mar 7, 2006	Roof Matrix, Inc.	Non-toxic hydrophobic elastomeric polymer chemistry system for wood preservation
United States of America	12/244,272	8,771,725	Jul 8, 2014	CHESSON LABORATORY ASSOCIATES, INC.	Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
United States of America	14/229,341	9,259,436	Feb 16, 2016	CHESSON LABORATORY ASSOCIATES, INC.	Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same
United States of America	14/891,311	10,987,376	April 27, 2021	CHESSON LABORATORY ASSOCIATES, INC.	Methods of treating and/or preventing nail disorders and/or improving the appearance of a nail.
Canada	2912538	2912538	Sept. 10, 2019	CHESSON LABORATORY ASSOCIATES, INC.	Methods of treating and/or preventing nail disorders and/or improving the appearance of a nail

Rhofade Trademarks owned by EPI Health

MARK	COUNTRY	STATUS	APPLICATION #	REGISTRATION #
RHOFADE	Japan	Registered	2014-070814	5734254
RHOFADE	Australia	Registered	1638800	1638800
RHOFADE	Canada	Registered	1680849	1034440
RHOFADE	United States of America	Registered	86/306966	5232934
RHOFADE	Brazil	Registered	908069014	908069014
RHOFADE	European Union	Registered	13195136	13195136
RHOFADE	United Kingdom	Registered	13195136	UK00913195136

TRADEMARK

REEL: 007943 FRAME: 0762

RECORDED: 01/11/2023